{"denoms":[{"counts":[{"groupId":"BG000","value":"20"}],"units":"Participants"}],"groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"BG000","title":"Bevacizumab, Radiation, and Surgery"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13","value":"54"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Fibroblastic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"Liposarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"}]}],"title":"Leiomyosarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Fibroblastic Osteosarcoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Not Otherwise Specified"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sarcoma Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Low"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}]}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"}]}],"title":"High"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sarcoma Grade","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"5","upperLimit":"20.2","value":"8.25"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Median Sarcoma Size","unitOfMeasure":"Centimeters (cm)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"}]}],"title":"Extremity"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Trunk"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}]}],"title":"retroperitoneal/pelvis tumors"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sarcoma Location","unitOfMeasure":"Participants"}]}